GLP-1 TV · Patient story · 5 videos
Beat The Denominator
@BeatTheDenominator on YouTube ↗Beat The Denominator is a YouTube channel of people sharing their own GLP-1 experience, with 23.9K subscribers. GLP-1 TV holds 5 of its videos, 13.4K views between them, the newest from Apr 2025. The speaker in most of them is Beat The Denominator, as the videos introduce them.
- Medications covered
- Ozempic (1), Mounjaro (1)
- Topics that come up most
- Cost and insurance, Injection technique, Stopping and maintenance, Exercise and strength, Side effects, Food noise and cravings
15:34LifeMD Crashes -27% on GLP-1 Fears... Why I'm Buying The Dip! (LFMD Stock Analysis)Beat The DenominatorDetails6 key moments
The creator of the Beat The Denominator channel explains why they bought LifeMD (LFMD) after the stock fell 27% on a Friday.
- 0:00 Analyzing the stock crash
- 0:57 GLP-1 and FDA news
- 2:36 Core thesis for LifeMD
- 5:28 RexMD men's health venture
- 6:56 GLP-1 strategy and insurance
- 11:03 Investment conclusion
- Prices mentioned: $39 a month and $99 a month
- Who is speaking: Patient
12:00Hims Stock Down -11% as GLP-1 Shortage Ends for Drug that Hims STILL DOESN'T SELL and NEVER SOLD!Beat The DenominatorDetails5 key moments
The creator of the Beat The Denominator channel says Hims stock fell 11% after the FDA moved tirzepatide off its drug shortage list, even though, according to the video, Hims does not sell tirzepatide and never has.
- 0:00 Addressing media misinformation
- 2:30 Hims business model reality
- 4:47 Market overreaction analysis
- 6:14 Future regulatory outlook
- 9:20 Growth strategy and conclusion
- Who is speaking: Patient
10:59Hims & Lilly's Tirzepatide: Perfect Match? What if Cmpnded Sema clients all switch to LLY's Tirze...Beat The DenominatorDetails5 key moments
According to the video, the creator reacts to a Bloomberg report that Hims is partnering to offer branded GLP-1s, specifically Zepbound (tirzepatide) from Lilly.
- 0:00 April Fools and news
- 0:30 Hims partners with Lilly
- 2:28 Impact on revenue guidance
- 5:00 Strategic plot twist
- 8:25 Injection pens and outlook
- Prices mentioned: $1900 a month and $499 a month
- Who is speaking: Patient
24:25Deep Dive on GLP-1s: Hims, Lilly, and Novo Nordisk. Are GLP-1s A Bigger Story Than Just Weight Loss?Beat The DenominatorDetails7 key moments
This video comes from the investing channel Beat The Denominator. The host explains how GLP-1 drugs work and why he thinks they matter beyond weight loss.
- 0:00 What do GLP-1s do? How does it work?
- 2:02 10% of Americans currently on some form of GLP-1? More soon?
- 3:15 Ranking the GLP-1s from most to least effective: Retatrutide
- 11:45 Novo trying to ban Compounded Semaglutide? People are stocki
- 16:14 People getting these drugs NOT for weight loss? Helps with i
- 22:15 Valuation of Hims vs. Nvo vs. Lily. Hims is my fave.
- 24:10 Thanks for watching!
- Who is speaking: Patient
5:20Hims Won't Sell Ozempic & Mounjaro For Weight Loss Just Yet. Why It's The Right Thing To DoBeat The DenominatorDetails
According to the video, the host of the Beat The Denominator channel looks at why Hims, whose CEO is named as Andrew Durham, has not started offering Ozempic or Mounjaro for weight loss.
- Who is speaking: Patient
Where semaglutide costs least today
The three cheapest partner programs for semaglutide, all in per month, checked weekly. Brand Ozempic and compounded versions are different products; each row says which it is.
What each Beat The Denominator video covers
The opening line of our summary for each video, most-watched first.
- LifeMD Crashes -27% on GLP-1 Fears... Why I'm Buying The Dip! (LFMD Stock Analysis)
The creator of the Beat The Denominator channel explains why they bought LifeMD (LFMD) after the stock fell 27% on a Friday.
4.2K views · Feb 2025 - Hims Stock Down -11% as GLP-1 Shortage Ends for Drug that Hims STILL DOESN'T SELL and NEVER SOLD!
The creator of the Beat The Denominator channel says Hims stock fell 11% after the FDA moved tirzepatide off its drug shortage list, even though, according to the video, Hims does not sell tirzepatide and never has.
3.8K views · Dec 2024 - Hims & Lilly's Tirzepatide: Perfect Match? What if Cmpnded Sema clients all switch to LLY's Tirze...
According to the video, the creator reacts to a Bloomberg report that Hims is partnering to offer branded GLP-1s, specifically Zepbound (tirzepatide) from Lilly.
2.9K views · Apr 2025 - Deep Dive on GLP-1s: Hims, Lilly, and Novo Nordisk. Are GLP-1s A Bigger Story Than Just Weight Loss?
This video comes from the investing channel Beat The Denominator.
1.7K views · Oct 2024 - Hims Won't Sell Ozempic & Mounjaro For Weight Loss Just Yet. Why It's The Right Thing To Do
According to the video, the host of the Beat The Denominator channel looks at why Hims, whose CEO is named as Andrew Durham, has not started offering Ozempic or Mounjaro for weight loss.
809 views · Apr 2023
Watched them? See what it costs.
Every GLP-1 program we track, ranked by what actually leaves your account.